Marshall Wace, LLP Greenwich Life Sciences, Inc. Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$12.12 - $20.8 $6,399 - $10,982	528 Added 1.24%	43,031 $593,000
Q4 2022 Feb 14, 2023	SELL	$9.04 - $16.88 $311,156 - $581,009	-34,420 Reduced 44.75%	42,503 $646,000
Q3 2022 Nov 14, 2022	SELL	$7.81 - $12.02 $100,069 - $154,012	-12,813 Reduced 14.28%	76,923 $702,000
Q2 2022 Aug 15, 2022	BUY	$7.14 - $20.36 $491,453 - $1.4 Million	68,831 Added 329.26%	89,736 $760,000
Q1 2022 May 16, 2022	BUY	$16.3 - $24.65 $51,931 - $78,534	3,186 Added 17.98%	20,905 $410,000
Q4 2021 Feb 14, 2022	BUY	$21.76 - $39.43 $385,565 - $698,660	17,719 New	17,719 $431,000

1.1M

Ticker GLSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,848,200
Market Cap $158M
Description
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.